Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab.
dc.contributor.author | Bennett, John M | |
dc.contributor.author | Kaminski, Mark S | |
dc.contributor.author | Leonard, John P | |
dc.contributor.author | Vose, Julie M | |
dc.contributor.author | Zelenetz, Andrew D | |
dc.contributor.author | Knox, Susan J | |
dc.contributor.author | Horning, Sandra | |
dc.contributor.author | Press, Oliver W | |
dc.contributor.author | Radford, John A | |
dc.contributor.author | Kroll, Stewart M | |
dc.contributor.author | Capizzi, Robert L | |
dc.date.accessioned | 2009-07-29T11:43:34Z | |
dc.date.available | 2009-07-29T11:43:34Z | |
dc.date.issued | 2005-06-15 | |
dc.identifier.citation | Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. 2005, 105 (12):4576-82 Blood | en |
dc.identifier.issn | 0006-4971 | |
dc.identifier.pmid | 15731177 | |
dc.identifier.doi | 10.1182/blood-2004-12-4690 | |
dc.identifier.uri | http://hdl.handle.net/10541/75822 | |
dc.description.abstract | The incidence of treatment-related myelodysplastic syndromes and acute myeloid leukemia (tMDSs/tAML) after tositumomab and iodine I(131) tositumomab administration to previously treated and untreated patients with non-Hodgkin lymphoma (NHL) was evaluated. A total of 1071 patients were enrolled in 7 studies: 995 with relapsed/refractory low-grade NHL, +/- transformation (median, 3 prior regimens [range, 1-13 regimens]) and 76 patients with previously untreated low-grade follicular NHL. A single dose of iodine tositumomab and I(131) tositumomab was administered. For tMDS/tAML patients, baseline and posttherapy peripheral blood and marrow specimens were reviewed in a blinded fashion. Median follow-up was 6 years from diagnosis and 2 years from radioimmunotherapy (RIT) for previously treated patients, and 4.6 years from radioimmunotherapy for previously untreated patients. tMDS/tAML was reported in 35 (3.5%) of 995 patients (annualized incidence, 1.6%/y [95% confidence interval, 1.0%-2.0%/y]), and 52% of the tMDS/tAML diagnoses of tMDS/tAML were confirmed in a blinded review (annualized incidence of 1.1%/y [95% confidence interval, 0.7%-1.6%/y]). Of the 25 cases, 10 patients (40%) were diagnosed with tMDS/tAML prior to receiving radioimmunotherapy; 2 (8%) had no pathologic or clinical evidence to support such a diagnosis; and 13 (52%) were confirmed to have developed tMDS/tAML following RIT. This incidence is consistent with that expected on the basis of patients' prior chemotherapy for NHL. With a median follow-up approaching 5 years, no case of tMDS/tAML has been reported in any of the 76 patients receiving iodine I(131) tositumomab as their initial therapy (P = .011 compared with previously treated patients). | |
dc.language.iso | en | en |
dc.subject | Leukaemia | en |
dc.subject.mesh | Adult | |
dc.subject.mesh | Aged | |
dc.subject.mesh | Aged, 80 and over | |
dc.subject.mesh | Antibodies, Monoclonal | |
dc.subject.mesh | Antineoplastic Agents | |
dc.subject.mesh | Clinical Trials as Topic | |
dc.subject.mesh | Disease-Free Survival | |
dc.subject.mesh | Female | |
dc.subject.mesh | Follow-Up Studies | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Incidence | |
dc.subject.mesh | Iodine Radioisotopes | |
dc.subject.mesh | Leukemia, Myeloid, Acute | |
dc.subject.mesh | Lymphoma, Non-Hodgkin | |
dc.subject.mesh | Male | |
dc.subject.mesh | Middle Aged | |
dc.subject.mesh | Models, Statistical | |
dc.subject.mesh | Myelodysplastic Syndromes | |
dc.subject.mesh | Radioimmunotherapy | |
dc.subject.mesh | Radiometry | |
dc.subject.mesh | Remission Induction | |
dc.subject.mesh | Time Factors | |
dc.subject.mesh | Whole-Body Irradiation | |
dc.title | Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. | en |
dc.type | Article | en |
dc.contributor.department | James P. Wilmot Cancer Center, University of Rochester School of Medicine, Rochester, NY 14642, USA. john_bennett@urmc.rochester.edu <john_bennett@urmc.rochester.edu> | en |
dc.identifier.journal | Blood | en |
html.description.abstract | The incidence of treatment-related myelodysplastic syndromes and acute myeloid leukemia (tMDSs/tAML) after tositumomab and iodine I(131) tositumomab administration to previously treated and untreated patients with non-Hodgkin lymphoma (NHL) was evaluated. A total of 1071 patients were enrolled in 7 studies: 995 with relapsed/refractory low-grade NHL, +/- transformation (median, 3 prior regimens [range, 1-13 regimens]) and 76 patients with previously untreated low-grade follicular NHL. A single dose of iodine tositumomab and I(131) tositumomab was administered. For tMDS/tAML patients, baseline and posttherapy peripheral blood and marrow specimens were reviewed in a blinded fashion. Median follow-up was 6 years from diagnosis and 2 years from radioimmunotherapy (RIT) for previously treated patients, and 4.6 years from radioimmunotherapy for previously untreated patients. tMDS/tAML was reported in 35 (3.5%) of 995 patients (annualized incidence, 1.6%/y [95% confidence interval, 1.0%-2.0%/y]), and 52% of the tMDS/tAML diagnoses of tMDS/tAML were confirmed in a blinded review (annualized incidence of 1.1%/y [95% confidence interval, 0.7%-1.6%/y]). Of the 25 cases, 10 patients (40%) were diagnosed with tMDS/tAML prior to receiving radioimmunotherapy; 2 (8%) had no pathologic or clinical evidence to support such a diagnosis; and 13 (52%) were confirmed to have developed tMDS/tAML following RIT. This incidence is consistent with that expected on the basis of patients' prior chemotherapy for NHL. With a median follow-up approaching 5 years, no case of tMDS/tAML has been reported in any of the 76 patients receiving iodine I(131) tositumomab as their initial therapy (P = .011 compared with previously treated patients). |